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Background: Food allergy (FA) negatively affects quality of life in caregivers of food-allergic children, imposing a
psychosocial and economic burden. Oral immunotherapy (OIT) is a promising investigational therapy for FA. However,
OIT can be a source of anxiety as it carries risk for allergic reactions. The effect of OIT with multiple food allergens
(mOIT) on FA-specific health-related quality of life (HRQL) has never been studied in participants with multiple,
severe food allergies. This study is the first to investigate the effects of mOIT on FA-related HRQL in caregivers
of pediatric subjects.
Methods: Caregiver HRQL was assessed using a validated Food Allergy Quality of Life – Parental Burden (FAQL-PB)
Questionnaire (J Allergy Clin Immunol 114(5):1159-1163, 2004). Parents of participants in two single-center Phase I clinical
trials receiving mOIT (n = 29) or rush mOIT with anti-IgE (omalizumab) pre-treatment (n = 11) completed the FAQL-PB
prior to study intervention and at 2 follow-up time-points (6 months and 18 months). Parents of subjects not receiving
OIT (control group, n = 10) completed the FAQL-PB for the same time-points.
Results: HRQL improved with clinical (change < −0.5) and statistical (p < 0.05) significance in the mOIT group (baseline
mean 3.9, 95% CI 3.4-4.4; 6-month follow-up mean 2.5, 95% CI 2.0-3.0; 18-month follow-up mean 1.8, 95% CI 1.4-2.1) and
rush mOIT group (baseline mean 3.9, 95% CI 3.1-4.7; 6-month follow-up mean 1.7, 95% CI 0.9-2.6; 18-month follow-up
mean 1.3, 95% CI 0.3-2.4). HRQL scores did not significantly change in the control group (n = 10).
Conclusion: Multi-allergen OIT with or without omalizumab leads to improvement in caregiver HRQL, suggesting that
mOIT can help relieve the psychosocial and economic burden FA imposes on caregivers of food-allergic children.
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quality of lifeIntroduction
Food allergy (FA) is an adverse immunologic response to
dietary antigen with a reported prevalence of 8% in the
United States. Approximately 30.4% of food-allergic par-
ticipants are multi-sensitized, or allergic to more than one
food allergen [1]. In Canada, the prevalence of pediatric
food allergy has been reported to be 7.14% [2]. Currently,* Correspondence: knadeau@stanford.edu
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unless otherwise stated.the only FDA-approved treatment for FA is food allergen
avoidance and injectable epinephrine [3].
Food allergies have a significant negative impact on
participants’ quality of life [4-6]. The burden of FA on
caregivers (buying special foods, limiting social encoun-
ters, foregoing full-time employment) has been reported
to play a predominant role in the total annual economic
burden of FA, $24.8 billion [7]. Compared to those with
single food allergies, those with multiple food allergies
experience a greater decrease in quality of life [5,8], are
more likely to suffer from dietary deficiencies [9] and are
less likely to outgrow their food allergies [10].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tional therapy for food allergy [11]. We recently con-
ducted two Phase I clinical trials showing the safety and
feasibility of 1) an OIT protocol for desensitization to
multiple allergens simultaneously (mOIT) [12] and 2) a
protocol combining anti-IgE therapy (omalizumab) and
a rush mOIT schedule to allow a rapid desensitization
(rush mOIT) [13].
Although it is intuitive to think that successful
desensitization to multiple food allergens would im-
prove quality of life, safety analyses have shown that aller-
gic reactions are common with OIT dosing. Although the
majority of reactions are reported as mild, events requir-
ing injectable epinephrine do occur [12,13]. This raises
the question as to whether reactions with dosing outweigh
the benefit gained from therapy, which can only be ad-
dressed by an objective evaluation of quality of life influ-
enced specifically by health and disease, or health-related
quality of life (HRQL) [14-16]. While single-allergen OIT
has been found to result in HRQL improvement in partici-
pants with peanut or cow milk allergy [17,18], this study is
the first to investigate the effects of mOIT and of rush
mOIT with omalizumab on FA-related HRQL.
Methods
Participants
Questionnaires were distributed to caregivers of 3 groups of
participants: 2 experimental groups enrolled in 2 separate
ongoing single-center Phase I clinical trials conducted under
INDs with Stanford IRB approvals and 1 control group
whose only intervention was food allergen avoidance.
Written consent was obtained prior to study entry.
Eligibility criteria are described in detail in previous
publications [12,13]. Briefly, in all the groups, partici-
pants older than 4 years were eligible for inclusion if
they had proven sensitivity to their main food allergen
documented by both a positive skin prick test specific
IgE as well as positive allergic reaction in a double-blind
placebo-controlled oral food challenge (DBPCFC) up to a
cumulative dose of 182 mg as per Bock’s criteria [12,13].
To be included in the treatment, additional food allergens
also needed to induce a reaction within a cumulative dose
of 182 mg on DBPCFC.
Study intervention
The intervention and medication used in the mOIT and
rush mOIT groups have been described in detail previ-
ously [12,13]. Briefly, subjects meeting inclusion criteria
were started on a daily dose of up to 5 multiple food al-
lergens combined in an equivalent stoichiometric ratio
(1:1:1:1:1) based on food protein content. In the mOIT
group, participants underwent an initial dose escalation
starting at 0.1 mg of total food protein up to a maximum of
6 mg if tolerated. The maximal tolerated dose determineddaily home dose that was increased by 25% increments
every other week at our research clinic based on dose toler-
ability. Participants took a median of 85 weeks to reach their
maintenance dose of 4000 mg protein per food. In the rush
mOIT group, participants underwent a 16-week omalizu-
mab treatment, starting 8 weeks prior to rush mOIT. They
underwent rush desensitization up to 1250 mg of total food
protein on their first day, followed by similar biweekly in-
creases in home doses. Final maintenance dose was reached
at a median of 18 weeks.
Questionnaire
Health-related quality of life (HRQL) was assessed
using a validated Food Allergy Quality of Life – Parental
Burden (FAQL-PB) Questionnaire [1]. The FAQL-PB is a
FA-specific HRQL questionnaire that measures parental
burden associated with having a child with FA. It was ori-
ginally validated in the United States by Cohen et al. and
consists of 17 questions that are answered on a 7-point
scale.
All patients in the mOIT and the rush mOIT trials
who started the protocol between January 1 and April 1
2012 were asked to complete the questionnaire prior to
study intervention. The same parent who filled out the
questionnaire at baseline completed the subsequent
follow-up questionnaires at a 6-month follow-up time-
point on OIT and an 18-month follow-up time-point.
Only caregivers of participants aged less than 17-years
were included to be consistent with the age group used
in the validation phase of the FAQL-PB questionnaire by
Cohen et al. [1].
During the same period, all consecutive subjects screened
and meeting the same inclusion criteria as the mOIT and
rush mOIT trials were asked to fill out the questionnaire.
Those who were not included in the mOIT and rush mOIT
trials despite meeting inclusion criteria due to lack of avail-
able space were asked to fill out follow-up questionnaires
as an untreated control group.
Statistics
Comparisons between HRQL scores were made with the
Wilcoxon for paired variables and the Mann–Whitney
test for unpaired variables, as appropriate. A 2-tailed
p-value of less than 0.05 was considered statistically
significant.
Clinical relevance was assessed using the MID, or min-
imal clinically important difference. The MID has previ-
ously been defined as the smallest change in HRQL that
participants perceive as clinically important. It has been
estimated to be approximately 0.5 for scores graded on a
7-point scale in several HRQL questionnaires, including
questionnaires assessing parental quality of life [19-23].
The therapeutic value of oral immunotherapy was deter-
mined by calculating the number-needed-to-treat (NNT)
Table 1 Baseline demographics and clinical characteristics of
pediatric subjects in the mOIT, rush mOIT, and control
groups
mOIT* Rush mOIT* Control
Number of subjects 29 11 10
Median age in years
(range)
8 (4 – 13) 7 (4 – 16) 8 (4–14)
Male 18 (62%) 8 (72%) 5 (50%)
Coexisting atopic disease
Atopic dermatitis 20 (69%) 5 (45%) 5 (50%)
Allergic rhinitis 15 (52%) 6 (55%) 6 (60%)
Asthma 21 (72%) 8 (73%) 7 (70%)
Food allergies meeting criteria for inclusion on DBPCFC**
Peanut 20 (69%) 7 (64%) 7 (70%)
Walnut 11 (38%) 5 (45%) 4 (40%)
Cashew 9 (31%) 6 (55%) 3 (30%)
Pecan 8 (28%) 5 (45%) 3 (30%)
Milk 8 (28%) 3 (27%) 2 (20%)
Egg 4 (14%) 4 (36%) 3 (30%)
Sesame 4 (14%) 0 (0%) 2 (20%)
Almond 3 (10%) 3 (27%) 2 (20%)
Hazelnut 2 (7%) 1 (9%) 2 (20%)
Average number of desensitized foods
3 4 n/a
Highest baseline food allergy test (median and range)
SPT in mm 13.5 (7–25.5) 10.5 (7–29.5) 10.5 (7–30.5)
Specific IgE in ku/L 82.5 (2.95- > 100) 36.4 (2- > 100) 61 (3.25- > 100)
Lowest amount
triggering reaction in
DBPCFC in mg protein
32.7 (0.1-182.7) 32.7 (0.1-182.7) 32.7 (0.1-182.7)
*OIT = oral immunotherapy. **DBPCFC=double blind placebo controlled
food challenge.
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proportion of participants who benefited from multi-
allergen oral immunotherapy was calculated as the dif-
ference of the proportion of participants with clinically
important improvement in HRQL in the mOIT group
minus the proportion of participants with improve-
ment in HRQL in the control group. The NNT is the
reciprocal of the proportion of participants benefiting
from OIT. All statistical analyses and graphing were
carried out with GraphPad Prism software (GraphPad
Software, San Diego, CA).
Results
During the initial recruitment period for the HRQL study,
29 participants started the mOIT trial and 11 participants
started the rush mOIT trial. Caregivers of all these partici-
pants completed the FAQL-PB questionnaire at all required
time-points. During the same period, 24 participants were
screened and met criteria for entry into an OIT trial at our
center. All caregivers accepted to complete the question-
naire as controls. Fourteen were eventually included in a
trial prior to 6-month follow-up and were thus excluded
from analysis. Of the 10 remaining participants, 2 were lost
to follow-up prior to the 18-month follow-up. Baseline
characteristics were similar between all 3 groups (Table 1).
At baseline, all three groups had a high and compar-
able HRQL score (mean 3.6 to 3.9) out of a maximum of
6, indicating that all groups had a poor quality of life at
baseline. Caregivers of participants in the mOIT group
(n = 29) had a significant improvement in HRQL score
at 6-month follow-up (mean 2.5, 95% CI 2.0-30) and
18-month follow-up (mean 1.8, 95% CI 1.4-2.1) com-
pared to baseline (p < 0.0001). Caregivers of participants in
the rush mOIT group (n = 11) also had a significant im-
provement in HRQL score at 6-month follow-up (mean 1.7,
95% CI 0.9-2.6) and 18-month follow-up (mean 1.3, 95% CI
0.3-2.4) compared to baseline (p = 0.001 and p = 0.005,
respectively). HRQL worsened significantly (p < 0.01)
in the control group (n = 10) from baseline (mean 3.6,
95% CI 2.9-4.3) to 6-month follow-up (mean 4.3, 95%
CI 3.9-4.8). However, HRQL at 18-month follow-up
(mean 4.3, 95% CI 3.7-4.7) was comparable to baseline
HRQL in the control group (Figure 1). We did not find any
association between the number of foods or adverse events
and the change in HRQL score in either group although we
may have lacked power for such sub-group analysis.
With both interventions, the improvement was clinically
relevant (decrease greater than −0.5) at both time points
(−1.9 and −2.5 at 6 and 18 months with mOIT, −2.6
and −3.1 at 6 and 18 months with rush mOIT). The per-
centages of participants with clinically relevant changes in
FAQL-PB HRQL scores are shown for all 3 groups in
Figure 2A (6-month follow-up) and Figure 2B (18-month
follow-up).To assess therapeutic value, we calculated the NNT to
induce a clinically relevant improvement in QOL. At the
6-month follow-up time-point, NNT for mOIT was 1.5
and 1.1 for rush multi-allergen OIT. At the 18-month
follow-up time-point, NNT was 1.2 for both multi-allergen
OIT and rush multi-allergen OIT.
We looked at individual question scores to see if changes
seen in overall HRQL scores were distributed across all
questions or due to changes in specific question scores
(Figure 3). In the mOIT group, caregivers’ answers showed
a statistically significant (p < 0.05) and clinically relevant
(change < −0.5) change for all 17 questions (Additional file
1: Table S1) at the 6-month follow-up that persisted at the
18-month follow-up. Similarly, in the rush mOIT group,
caregivers’ answers showed a statistically significant and
clinically relevant change for all but 2 questions at the
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Figure 1 HRQL scores improve in caregivers of participants on
mOIT and rush mOIT. Median HRQL score at baseline, 6-month
follow-up, and 18-month follow-up are shown for the control group,
mOIT group, and rush mOIT group. Whiskers represent minimum
and maximum values. Median HRQL scores were 3.6, 4.4, 4.2 at
baseline, 6 months, and 18 months, respectively, for the control
group; 4.3, 2.4, 1.8 for the mOIT group; 3.9, 1.3, 0.8 for the rush
mOIT group. ** p < 0.01, *** p = 0.001, **** p < 0.0001.
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Using a quality of life questionnaire specifically validated
for food allergy, we have shown that two protocols for
mOIT were associated with clinically and statistically sig-
nificant increases in caregiver quality of life. This change
persisted with 18 months of ongoing therapy and included





















































Figure 2 Percentages of participants with deterioration, no change, o
HRQL scores deteriorated (change > 0.5), remained unchanged (change be
mOIT group, and rush mOIT group at (A) 6-month follow-up and (B) 18-mpronounced after 18 months of rush mOIT combined with
Omalizumab which showed a HRQL score decrease of 3.1
from median 3.9 to 0.8 (score ranked on a maximum of 6).
These findings are of major importance given the
current question surrounding the role for OIT in the
care for children with multiple food allergies. The efficacy
of OIT is typically measured by the ability to tolerate food
allergen after discontinuation of therapy (clinical tolerance
or sustained unresponsiveness). Recent studies have shown
limited rates of sustained unresponsiveness with OIT, rais-
ing concern about its relevance as an intervention for food
allergy [26]. This study shows that desensitization itself,
even without discontinuing therapy, provides significant
and persistent improvement in caregiver quality of life.
This suggests OIT can be of benefit to caregiver quality of
life even in the absence of sustained unresponsiveness.
These results also suggest that the reaction profiles of
mOIT and rush mOIT are acceptable and justified from
a caregiver point-of-view and are much preferred to al-
lergen avoidance. Home dosing reactions, which are ex-
pected and for which the patient is prepared may be less
anxiety-producing than the constant fear of accidental
reactions and uncertainty of day to day living with food
allergy. In a review of 352 subjects desensitized to pea-
nut, Wasserman and colleagues showed that severe reac-
tions requiring epinephrine in the context of OIT were
recognized and treated promptly and did not require
additional intervention [27].ush mOIT
9%
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Figure 3 Changes in individual FAQL-PB question scores. Changes in individual FAQL-PB question scores are shown between and (A) 6-month
follow-up and (B) 18-month follow-up. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Bars without asterisks represent non-significant changes.
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PB questionnaire showed that mOIT had an impact on
various aspects of day to day living associated with an
economic burden for families with food allergy. These
include arranging special diets ($1.7 billion spent an-
nually in the United States) and avoidance of uninten-
tional exposure to food allergens including childcare
arrangements ($857 million), changing schools ($650
million), and attending special summer camps ($125
million) [8].This study is the first to examine the effects of multi-
allergen OIT protocols in caregivers of multi-sensitized
participants. Two prior studies showed improvement in
FA-specific HRQL with single-allergen OIT. These stud-
ies used a different questionnaire so their results cannot
be directly compared to those presented here. To the
best of our knowledge, the effect of single-allergen oral
immunotherapy on HRQL has never been studied in
participants with multiple, severe food allergies but one
could assume that the effect would not be as drastic
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one of their food allergens.
When comparing the two interventions, the magni-
tude of improvement was greater for the rush mOIT
group, especially at the 6-month time point. Also, at 6-
month follow-up, a larger percentage of participants had
improved HRQL scores in the rush mOIT group (91%)
when compared to the mOIT (66%) group, whereas at
18-month follow-up, the percentage of participants with
improved HRQL scores was similar between the rush
mOIT (91%) and mOIT (84%) group. The greater and
more rapid HRQL improvement with rush mOIT prob-
ably reflects the fact that subjects reach maintenance
much faster in this group (median 18 weeks) compared
to mOIT without omalizumab (median 85 weeks)
[12,13]. It is unlikely to be related to a protective effect
of omalizumab as reaction rates were similar in both
groups.
One limitation to consider is that all subjects were re-
cruited from volunteers. Although this potentially intro-
duced selection bias toward more severely affected families,
this bias reflects the patient population that would seek out
additional therapy such as oral immunotherapy. Also, these
were Phase I studies. Although the control group was not
placebo-controlled, it would not have been possible to test
the full psychosocial effect of the intervention if subjects
were blinded and did not know they were protected. Des-
pite the control group being comparable and selected using
the same criteria, it is possible that the intense follow-up
with bi-weekly visits to see food allergy specialists dur-
ing OIT escalation phase positively affected the treat-
ment group caregiver quality of life. However, previous
studies looking at allergist interventions such as DBPCFC
(positive outcome) and self-regulation telephone interven-
tion did not show significant impact on overall HRQL
scores [22,28].
In conclusion, our findings suggest that mOIT, with or
without omalizumab, can lead to significant improvements
in caregiver HRQL that persist with ongoing treatment.
These findings support OIT as a promising therapy for
food allergy and suggest that OIT can help relieve the psy-
chosocial burden food allergy imposes on caregivers of
food-allergic children. Validated measures of quality of life
should be included in future phase II clinical trials.Additional file
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